63-39-8

基本信息
URIDINE 5'-TRIPHOSPHATE
URIDINE-5'-TRIPHOSPHATE NA3-SALT
URIDINE-5'-TRIPHOSPHATE SODIUM
URIDINE 5'-TRIPHOSPHATE SODIUM SALT
URIDINE 5-TRIPHOSPHATE TRISODIUM
URIDINE-5'-TRIPHOSPHATE TRISODIUM SALT
URIDINE-5'-TRIPHOSPHORIC ACID, TRISODIUM
UTP
UTP, 3NA
UTP-NA
UTP, NA3H
UTP SODIUM SALT
UTP TRISODIUM SALT
5’-utp
uridine,5’-(tetrahydrogentriphosphate)
uridine5’-triphosphoricacid
uridinetriphosphate
uteplex
Uracylic
物理化学性质
密度 | 2.106±0.06 g/cm3(Predicted) |
闪点 | 113 °C |
储存条件 | −20°C |
溶解度 | Easily soluble (water) |
酸度系数(pKa) | pK1:7.58 (25°C) |
形态 | 液体 |
颜色 | 无色 |
生物来源 | yeast (Candida Utilis) |
水溶解性 | Water : ≥ 150 mg/mL (309.83 mM) |
CAS 数据库 | 63-39-8(CAS DataBase Reference) |
EPA化学物质信息 | Uridine 5'-(tetrahydrogen triphosphate) (63-39-8) |
安全数据
危险品标志 | Xn |
危险类别码 | R20/21/22-R68/20/21/22 |
安全说明 | S22-S26-S36 |
WGK Germany | 1 |
知名试剂公司产品信息
尿苷5'-三磷酸酯价格(试剂级)
报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
2025/02/08 | HY-107372 | 尿苷5'-三磷酸酯 Uridine triphosphate | 63-39-8 | 5 mg | 375元 |
2025/02/08 | HY-107372 | 尿苷5'-三磷酸酯 Uridine triphosphate | 63-39-8 | 10mg | 600元 |
2025/02/08 | HY-107372 | 尿苷5'-三磷酸酯 Uridine triphosphate | 63-39-8 | 50mg | 1200元 |
常见问题列表
Human Endogenous Metabolite
|
Uridine triphosphate treatment induces Schwannoma cell migration through activation of P2Y2 receptors and through the increase of extracellular matrix metalloproteinase-2 (MMP-2) activation and expression. Uridine triphosphate-induced proliferation is mediated by protein kinase D, Src-family tyrosine kinase, Ca/calmodulin-dependent protein kinase II, phosphatidylinositol 3-kinase (PI3K), Akt, and phospholipase D. Uridine triphosphate increases phosphorylation of Akt through protein kinase C, Src-family tyrosine kinase, Ca/calmodulin-dependent protein kinase II, and PI3K.
Uridine triphosphate reduces mitochondrial calcium levels following hypoxia. Early or late uridine triphosphate preconditioning is effective to reduce infarct size and superior myocardial function. Uridine triphosphate treatment increases the number of monocytes and macrophages infiltrating the pouch and up-regulates the gene expression of IL-4 and IL-13 in the regional lymph nodes.